Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

被引：0
|
作者：
Huyghe, N. [1 ]
Benidovskaya, E. [1 ]
Masoodi, T. [2 ]
Carrasco, J. [3 ]
De Cuyper, A. [4 ]
Sinapi, I. [3 ]
Vempalli, F. [2 ]
Verstraelen, E. [5 ]
Goffette, P. [5 ]
Ghaye, B. [5 ]
Papier, M.
Bedognetti, D. [2 ]
van Maanen, A. [5 ]
Castella, M-L. [5 ]
Galon, J. [6 ]
van den Eynde, M. [4 ]
机构：
[1] UCLouvain Univ Catholique Louvain, IIREC MIRO ONCO, Woluwe St Lambert, Belgium
[2] Sidra Med & Res Ctr, Al Rayyan, Qatar
[3] GHdC Grand Hop Charleroi Site Notre Dame, Med Oncol Dept, Charleroi, Belgium
[4] Clin Univ St Luc UCLouvain St Luc, Digest Oncol Dept, Woluwe St Lambert, Belgium
[5] Inst Roi Albert II Clin Univ St Luc, St Luc, Brussels, Belgium
[6] Cordeliers Res Ctr, Lab Integrat Canc Immunol, INSERM Team 15, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2237P
引用
收藏
页码：S1152 / S1152
页数：1
相关论文
共 50 条
  • [21] Fruquintinib plus sintilimab in refractory repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Preliminary clinical results and biomarker analyses from a phase II study
    Zhang, W.
    Sun, Y.
    Jiang, Z.
    Liu, T.
    Gong, C.
    Yang, L.
    Xin, Y.
    Huang, D.
    Zhou, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S728 - S728
  • [22] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI with or without bevacizumab (BV) in previously treated patients (pts) with metastatic colorectal cancer (mCRC).
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [23] Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
    Bocobo, Andrea Grace
    Wang, Renee
    Behr, Spencer
    Carnevale, Julia C.
    Cinar, Pelin
    Collisson, Eric Andrew
    Fong, Lawrence
    Kidder, Wesley Allen
    Ko, Andrew H.
    Kolli, Kanti Pallav
    Kennedy, Megan
    Laffan, Angela
    Lindsay, Sheila
    Nalla, Sneha
    Schwartz, Gabriel
    Whitman, Julia
    Zendejas, Patricia
    Zhang Li
    Van Loon, Katherine
    Atreya, Chloe Evelyn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [24] Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Haymaker, Cara L.
    Parra, Edwin R.
    Soto, Luisa Maren Solis
    Wang, Xuemei
    Thomas, Jane, V
    Dasari, Arvind
    Morris, Van K.
    Raghav, Kanwal
    Vilar, Eduardo
    Kee, Bryan K.
    Eng, Cathy
    Parseghian, Christine M.
    Wolff, Robert A.
    Lee, Younghee
    Lorenzini, Daniele
    Laberiano-Fernandez, Caddie
    Verma, Anuj
    Lang, Wenhua
    Wistuba, Ignacio I.
    Futreal, Andrew
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
  • [25] Exploratory biomarker analyses in phase 1 study of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Ye, Jian
    Wang, Chongkai
    Egelston, Colt
    Guo, Weihua
    Lee, Peter P.
    Fakih, Marwan
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Rechallenge with cetuximab (cet) plus irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet plus iri: the phase II CRICKET study by GONO
    Santini, D.
    Cremolini, C.
    Salvatore, L.
    Lonardi, S.
    Dell'Aquila, E.
    Cattaneo, M.
    Loupakis, F.
    Rossini, D.
    Vincenzi, B.
    Ziampiri, S.
    Buoro, V.
    Tamburini, E.
    Basile, D.
    Corsi, D. C.
    Fioroni, I.
    Masi, G.
    Borelli, B.
    Del Re, M.
    Tonini, G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Uronis, H. E.
    Morse, M. A.
    Blobe, G.
    Aklilu, M.
    Nixon, A.
    Niedzweicki, D.
    Honeycutt, W.
    Howard, L.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    Campbell, Jenny C.
    Shah, Manish A.
    Capanu, Marinela
    Kelsen, David P.
    Ilson, David H.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 126 - 130
  • [29] A phase II study of cetuximab (cet) and mFOLFOX6 in metastatic colorectal cancer (mCRC) (JACCRO CC-05)
    Yamaguchi, Tatsuro
    Tsuji, Akihito
    Sunakawa, Yu
    Nakamura, Masato
    Kochi, Mitsugu
    Denda, Tadamichi
    Shimada, Ken
    Tani, Satoshi
    Takagane, Akinori
    Kotaka, Masahito
    Kuramochi, Hidekazu
    Koike, Junichi
    Furushima, Kaoru
    Yonemura, Yutaka
    Negoro, Yuji
    Takinishi, Yasutaka
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] A PHASE IB EXPANSION COHORT OF PIXATIMOD PLUS NIVOLUMAB IN PREVIOUSLY TREATED, MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER (MSS MCRC)
    Lemech, Charlotte
    Dredge, Keith
    Bampton, Darryn
    Hammond, Edward
    Clouson, Andrew
    Waterhouse, Nigel
    Stanley, Amanda
    Leveque-ElMouttie, Lucie
    Chojnowski, Grace
    Haydon, Andrew
    Pavlakis, Nick
    Burge, Matthew
    Brown, Michael
    Goldstein, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A367 - A367
12345